Evidence map›Paper›PMID 37352385›Full record

ArticleCancer research2023

Whole Slide Imaging-Based Prediction of TP53 Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer.

Marija Pizurica, Maarten Larmuseau, Kim Van der Eecken, Louise de Schaetzen van Brienen, Francisco Carrillo-Perez, Simon Isphording, Nicolaas Lumen, Jo Van Dorpe, Piet Ost, Sofie Verbeke and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Marija PizuricaInternet Technology and Data Science Lab (IDLab/IMEC), Ghent University, Gent, Belgium.ORCID 0000-0002-6653-4094
Maarten LarmuseauInternet Technology and Data Science Lab (IDLab/IMEC), Ghent University, Gent, Belgium.ORCID 0000-0003-0466-099X
Kim Van der EeckenDepartment of Urology, Ghent University Hospital, Ghent, Belgium.ORCID 0000-0002-4070-2512
Louise de Schaetzen van BrienenInternet Technology and Data Science Lab (IDLab/IMEC), Ghent University, Gent, Belgium.ORCID 0000-0002-5882-9458
Francisco Carrillo-PerezDepartment of Architecture and Computer Technology (ATC), University of Granada, Granada, Spain.ORCID 0000-0003-0974-4092
Simon IsphordingInternet Technology and Data Science Lab (IDLab/IMEC), Ghent University, Gent, Belgium.ORCID 0009-0006-4120-6648
Nicolaas LumenDepartment of Urology, Ghent University Hospital, Ghent, Belgium.ORCID 0000-0003-1242-3644
Jo Van DorpeDepartment of Urology, Ghent University Hospital, Ghent, Belgium.ORCID 0000-0001-8175-2930
Piet OstDepartment of Radiotherapy, Ghent University Hospital, Ghent, Belgium.ORCID 0000-0002-2203-4848
Sofie VerbekeDepartment of Urology, Ghent University Hospital, Ghent, Belgium.ORCID 0000-0002-5402-8581
Olivier Gevaert *Department of Biomedical Data Science, Stanford University, School of Medicine, Stanford, California.ORCID 0000-0002-9965-5466
Kathleen Marchal *Internet Technology and Data Science Lab (IDLab/IMEC), Ghent University, Gent, Belgium.ORCID 0000-0002-2169-4588
Ghent University · BEGhent University Hospital · BEStanford Medicine · USUniversidad de Granada · ES

Funding

Multi-scale modeling of glioma for the prediction of treatment response, treatment monitoring and treatment allocationR01CA260271 · NCI · STANFORD UNIVERSITY · PI GEVAERT, OLIVIER · 2021 to 2025
$3.1M
NCI NIH HHS R01 CA260271
6 · The paper itself

Abstract

In prostate cancer, there is an urgent need for objective prognostic biomarkers that identify the metastatic potential of a tumor at an early stage. While recent analyses indicated TP53 mutations as candidate biomarkers, molecular profiling in a clinical setting is complicated by tumor heterogeneity. Deep learning models that predict the spatial presence of TP53 mutations in whole slide images (WSI) offer the potential to mitigate this issue. To assess the potential of WSIs as proxies for spatially resolved profiling and as biomarkers for aggressive disease, we developed TiDo, a deep learning model that achieves state-of-the-art performance in predicting TP53 mutations from WSIs of primary prostate tumors. In an independent multifocal cohort, the model showed successful generalization at both the patient and lesion level. Analysis of model predictions revealed that false positive (FP) predictions could at least partially be explained by TP53 deletions, suggesting that some FP carry an alteration that leads to the same histological phenotype as TP53 mutations. Comparative expression and histologic cell type analyses identified a TP53-like cellular phenotype triggered by expression of pathways affecting stromal composition. Together, these findings indicate that WSI-based models might not be able to perfectly predict the spatial presence of individual TP53 mutations but they have the potential to elucidate the prognosis of a tumor by depicting a downstream phenotype associated with aggressive disease biomarkers. SIGNIFICANCE: Deep learning models predicting TP53 mutations from whole slide images of prostate cancer capture histologic phenotypes associated with stromal composition, lymph node metastasis, and biochemical recurrence, indicating their potential as in silico prognostic biomarkers. See related commentary by Bordeleau, p. 2809.

Indexed as

Prostatic NeoplasmsHumansMaleMutationPhenotypePrognosisProstateTumor Suppressor Protein p53TP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID37352385
PMCPMC10538366
OpenAlexW4381839504

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.